SCHEMBL286235

SCHEMBL286235

[C]1OCCCC1C1CCCCO1

nearest known ligand 0.32

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
CHRM2 P08172 1/20 0.32
CHRM4 P08173 1/20 0.32
CHRM5 P08912 1/20 0.32
CHRM1 P11229 1/20 0.32
CHRM3 P20309 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL625617 0.96 CHRM2 (0.34) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL24752922 0.74 CHRM2 (0.43) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL3417328 0.73
SCHEMBL1621071 0.71 ALDH1A1 (0.32)
SCHEMBL176040 0.71 CHRM2 (0.39) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL9296811 0.70
SCHEMBL4009724 0.68 CHRM2 (0.31) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL15095887 0.68 CHRM2 (0.46) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL12700286 0.68 CHRM2 (0.46) CHRM2CHRM4CHRM5CHRM1CHRM3
SCHEMBL8515490 0.68 CHRM2 (0.46) CHRM2CHRM4CHRM5CHRM1CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024134515-A1 NOVEL COMPOUND AS RON INHIBITOR 주식회사 엘지화학 2024-06-27 WO claimed
US-10202345-B2 Substituted azaspiro(4.5)decane derivatives GRUENENTHAL GMBH (DE) 2019-02-12 US disclosed
US-10072180-B2 Composition for preparing article containing poly(imide-amide), method of preparing the same, and article containing poly(imide-amide) SAMSUNG ELECTRONICS CO., LTD. (KR) 2018-09-11 US disclosed
US-10059805-B2 Composition for preparing polyimide-inorganic particle composite, article prepared therefrom, and optical device comprising same SAMSUNG ELECTRONICS CO., LTD. (KR) 2018-08-28 US disclosed
US-20160222249-A1 COMPOSITION FOR PREPARING ARTICLE CONTAINING POLY(IMIDE-AMIDE), METHOD OF PREPARING THE SAME, AND ARTICLE CONTAINING POLY(IMIDE-AMIDE) SAMSUNG ELECTRONICS CO., LTD. (KR) 2016-08-04 US disclosed
US-20160096927-A1 COMPOSITION FOR PREPARING POLYIMIDE-INORGANIC PARTICLE COMPOSITE, ARTICLE PREPARED THEREFROM, AND OPTICAL DEVICE COMPRISING SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2016-04-07 US disclosed
US-20160016903-A1 Substituted Azaspiro(4.5)Decane Derivatives GRUENENTHAL GMBH (DE) 2016-01-21 US disclosed
US-9051315-B2 Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition ABBVIE INC. (US) 2015-06-09 US disclosed
US-20150152223-A1 POLYMER FOR OPTICAL FILM, AND OPTICAL FILM INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2015-06-04 US disclosed
EP-2427459-A1 ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
EP-2427458-A1 ISOXAZOLE-PYRIDAZINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2012-03-14 EP disclosed
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION ABBOTT LABORATORIES (US) 2011-05-26 US disclosed
US-20110112076-A1 SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS NOVARTIS AG (CH) 2011-05-12 US disclosed
EP-2318361-A1 SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS Novartis AG (CH) 2011-05-11 EP disclosed
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KIRIN CO., LTD. (JP) 2011-02-17 US disclosed
US-20050222093-A1 Methods for restoring cognitive function following systemic stress PEARLMAN RODNEY 2005-10-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222093-A1 Methods for restoring cognitive function following systemic stress CRH, BDNF, CHAT CHRM2 95/4885CHRM4 42/4885CHRM5 48/4885
US-20110039845-A1 2-AMINOQUINAZOLINE DERIVATIVE H1-2, H1-3, H1-0 CHRM2 585/4885CHRM4 2083/4885CHRM5 1277/4885
US-10202345-B2 Substituted azaspiro(4.5)decane derivatives OPRL1, OPRD1, OPRM1 CHRM2 627/4885CHRM4 544/4885CHRM5 244/4885
US-20110112076-A1 SELECTIVE HYDROXAMIC ACID BASED MMP-12 AND MMP-13 INHIBITORS MMP13, MMP11, MMP14 CHRM2 4793/4885CHRM4 4862/4885CHRM5 4835/4885
US-20160016903-A1 Substituted Azaspiro(4.5)Decane Derivatives OPRL1, OPRD1, OPRM1 CHRM2 627/4885CHRM4 544/4885CHRM5 244/4885
US-20110124632-A1 IMIDAZOPYRIDINES AS A NOVEL SCAFFOLD FOR MULTI-TARGETED KINASE INHIBITION PACSIN2, MAP4K2, MAP3K6 CHRM2 4641/4885CHRM4 4383/4885CHRM5 4716/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.